Anavex Life Sciences Corp.
AVXL | NASDAQ
$2.40
-$0.02 (-0.83%)
At close: Sep 21, 2026, 4:00 PM ET
$2.43
+$0.03 (+1.25%)
Pre-market:
Sep 22, 2026, 4:00 AM ET
Fiscal Year Period Ending | FY 2025 Sep 29, 2025 | FY 2024 Sep 29, 2024 | FY 2023 Sep 29, 2023 | FY 2022 Sep 29, 2022 | FY 2021 Sep 29, 2021 | FY 2020 Sep 29, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -51.41M | -52.88M | -55.76M | -50.99M | -42M | -31.09M |
Interest Income | 4.68M | 7.32M | 6.52M | 947K | 26K | 179.97K |
Pretax Income | -46.38M | -43M | -47.51M | -47.62M | -37.64M | -30.63M |
Net Income | -46.38M | -43M | -47.51M | -47.98M | -37.91M | -26.28M |
Selling & General & Admin | 13.82M | 11.04M | 12.05M | 13.07M | 9.02M | 5.86M |
Research & Development | 37.59M | 41.84M | 43.72M | 37.92M | 32.98M | 25.23M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 51.41M | 52.88M | 55.76M | 50.99M | 42M | 31.09M |
Interest Expense | n/a | n/a | 964K | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 51.41M | 52.88M | 55.76M | 50.99M | 42M | 31.09M |
Income Tax Expense | n/a | n/a | n/a | 358K | 268K | -4.35M |
Shares Outstanding (Basic) | 85.29M | 83.47M | 79.79M | 76.91M | 69.8M | 58.19M |
Shares Outstanding (Diluted) | 85.29M | 83.47M | 79.79M | 76.91M | 69.8M | 58.19M |
EPS (Basic) | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 | -0.45 |
EPS (Diluted) | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 | -0.45 |
EBITDA | -46.38M | -43M | -46.54M | -47.62M | -37.64M | -31.09M |
EBIT | -46.38M | -43M | -46.54M | -47.62M | -37.64M | -31.09M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove AVXL